CVRx unveils Barostim therapy process as Chief Medical Officer details device procedure

CVRx unveils Barostim therapy process as Chief Medical Officer details device procedure
CVRx unveils Barostim therapy procedure

CVRx introduces an overview of Barostim therapy through its Chief Medical Officer, Dr. Philip Adamson, MD, MSc, FACC, FESC, FRCP (Ed).

Dr. Adamson explains the key steps involved in the Barostim device procedure and its therapeutic application for patients suffering from heart failure. The review provides insight into how the technology delivers targeted therapy, aiming to improve patient outcomes in the management of chronic cardiac conditions.

Adamson recently discussed his career trajectory and developments in heart failure treatment during a medical podcast appearance. In a separate milestone, CVRx and The Mount Sinai Hospital completed their sixth Barostim implant, highlighting continued procedural adoption at the center (source). These events mark recent touchpoints in Barostim's clinical integration.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.